The Consortium brings together biopharmaceutical companies and federated learning technology to push the boundaries of AI-driven drug discovery.

• Leverage complementary industrial ADMET data beyond your own assays.
• Navigate from poor profiles or drop weak series earlier using better-calibrated ADMET predictions and uncertainty estimates on novel chemistry.
• Design more informative batches and use experimental capacity better in DMTA cycles.